{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:23:02Z","timestamp":1791321782830,"version":"4.3.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.intimp.2015.03.019","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T19:52:33Z","timestamp":1428263553000},"page":"185-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Rheumatoid arthritis: Biological therapy other than anti-TNF"],"prefix":"10.1016","volume":"27","author":[{"given":"Daniela","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Modena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2015.03.019_bb0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/art.1780190307","article-title":"Predominance of T cells in the lymphocytic infiltrates of synovial tissues in rheumatoid arthritis","volume":"19","author":"Bankhurst","year":"1976","journal-title":"Arthritis Rheum."},{"issue":"10","key":"10.1016\/j.intimp.2015.03.019_bb0010","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/art.1780311003","article-title":"Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis","volume":"31","author":"Cush","year":"1988","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2015.03.019_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.4049\/jimmunol.128.1.351","article-title":"Synovial fluid lymphocytes differ from peripheral blood lymphocytes in patients with rheumatoid arthritis","volume":"128","author":"Fox","year":"1982","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2015.03.019_bb0020","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM197509112931101","article-title":"Predominantly T-cell infiltrate in rheumatoid synovial membranes","volume":"293","author":"Van Boxel","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.03.019_bb0025","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jaut.2012.05.021","article-title":"Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction","volume":"39","author":"Boissier","year":"2012","journal-title":"J Autoimmun."},{"key":"10.1016\/j.intimp.2015.03.019_bb0030","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E","article-title":"Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium","volume":"42","author":"Chabaud","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.019_bb0035","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.10294","article-title":"Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion","volume":"46","author":"Moreland","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.019_bb0040","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.4049\/jimmunol.171.5.2581","article-title":"Functional plasticity of dendritic cell subsets as mediated by CD40 versus B7 activation","volume":"171","author":"Grohmann","year":"2003","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0045","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.172.7.4100","article-title":"Ligation of B7-1\/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells","volume":"172","author":"Munn","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0050","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","article-title":"Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kremer","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.019_bb0055","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","article-title":"Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial","volume":"144","author":"Kremer","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2015.03.019_bb0060","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1136\/ard.2007.080002","article-title":"Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate","volume":"67","author":"Schiff","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.019_bb0065","first-page":"553","article-title":"Long-term safety and efficacy of abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: a 7-year extended study","volume":"32","author":"Westhovens","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.autrev.2012.06.008","article-title":"Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry","volume":"12","author":"Atzeni","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.03.019_bb0075","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","article-title":"Tumor necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry","volume":"9","author":"Pallavicini","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.03.019_bb0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.autrev.2011.10.019","article-title":"Early treatment in early undifferentiated arthritis","volume":"11","author":"Olivieri","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.03.019_bb0085","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.autrev.2011.01.001","article-title":"Switching rheumatoid arthritis treatments: an update","volume":"10","author":"Atzeni","year":"2011","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.03.019_bb0090","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","article-title":"Immunogenicity and autoimmunity during anti-TNF therapy","volume":"12","author":"Atzeni","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2015.03.019_bb0095","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.clinthera.2010.10.011","article-title":"Safety profile of abatacept in rheumatoid arthritis: a review","volume":"32","author":"Khraishi","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.intimp.2015.03.019_bb0100","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1742-1241.2010.02612.x","article-title":"Tocilizumab: is there life beyond anti-TNF blockade?","volume":"65","author":"Alves","year":"2011","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.intimp.2015.03.019_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab \u2014 a novel therapy for non-organ-specific auto-immune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0110","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in rheumatology: new targeted therapeutics","volume":"13","author":"Tak","year":"2011","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2015.03.019_bb0115","first-page":"1426","article-title":"Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I\/II clinical study","volume":"30","author":"Nishimoto","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0120","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/ard.59.suppl_1.i21","article-title":"Anti-interleukin 6 receptor antibody treatment in rheumatic disease","volume":"59","author":"Nishimoto","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.019_bb0125","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1172\/JCI113921","article-title":"Synovium as a source of interleukin 6 in vitro: contribution to local and systemic manifestations of arthritis","volume":"83","author":"Guerne","year":"1989","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2015.03.019_bb0130","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"Hirano","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0135","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/art.1780310614","article-title":"Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides","volume":"31","author":"Houssiau","year":"1988","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.019_bb0140","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1136\/ard.52.3.232","article-title":"Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity","volume":"52","author":"Madhok","year":"1993","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.019_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00307733","article-title":"Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis","volume":"13","author":"Sack","year":"1993","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2015.03.019_bb0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/jbmr.5650110113","article-title":"Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation","volume":"11","author":"Kotake","year":"1996","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.intimp.2015.03.019_bb0155","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.intimp.2005.05.010","article-title":"Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family","volume":"5","author":"Mihara","year":"2005","journal-title":"Int. Immunopharmacol."},{"issue":"9617","key":"10.1016\/j.intimp.2015.03.019_bb0160","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","article-title":"Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial","volume":"371","author":"Smolen","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2015.03.019_bb0165","series-title":"Actemra Proscribing Information","year":"2013"},{"issue":"4","key":"10.1016\/j.intimp.2015.03.019_bb0170","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1136\/annrheumdis-2012-202469","article-title":"Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions","volume":"72","author":"Smolen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.03.019_bb0180","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2147\/PPA.S41433","article-title":"Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review","volume":"7","author":"Al-Shakarchi","year":"2013","journal-title":"Patient Prefer. Adherence"},{"issue":"1","key":"10.1016\/j.intimp.2015.03.019_bb0185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/annrheumdis-2013-203523","volume":"73","author":"Burmester","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2015.03.019_bb0190","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","article-title":"Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study","volume":"69","author":"Jones","year":"2010","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2015.03.019_bb0195","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3109\/07853890.2013.771986","article-title":"Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic disease","volume":"45","author":"Alten","year":"2013","journal-title":"Ann. Med."},{"issue":"5","key":"10.1016\/j.intimp.2015.03.019_bb0200","doi-asserted-by":"crossref","first-page":"R144","DOI":"10.1186\/ar2036","article-title":"Presence against cyclic citrullinated peptides in patients with Rhupus: a cross-sectional study","volume":"8","author":"Amezcua-Guerra","year":"2006","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2015.03.019_bb0205","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/096120339400300215","article-title":"What is the definition for coexistent rheumatoid arthritis and systemic lupus erythematosus?","volume":"3","author":"Satoh","year":"1994","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2015.03.019_bb0210","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1177\/0961203310392432","article-title":"Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus","volume":"20","author":"Eilertsen","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2015.03.019_bb0215","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.03.019_bb0220","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/BOR.0b013e3283369cb8","article-title":"B cells in the pathogenesis and treatment of rheumatoid arthritis","volume":"22","author":"Marston","year":"2010","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0225","doi-asserted-by":"crossref","first-page":"915e28","DOI":"10.1016\/j.berh.2006.05.010","article-title":"B cell depletion therapy in rheumatic disease","volume":"20","author":"Edwards","year":"2006","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0230","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.3899\/jrheum.101142","article-title":"Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry","volume":"38","author":"Markenson","year":"2011","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2015.03.019_bb0240","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jbspin.2014.06.011","article-title":"Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register","volume":"81","author":"Sebastiani","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2015.03.019_bb0245","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis","volume":"63","author":"Sellam","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.03.019_bb0250","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915001216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T06:32:39Z","timestamp":1691562759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915001216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1567576915001216"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.03.019","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rheumatoid arthritis: Biological therapy other than anti-TNF","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}